Metabolic brain pattern recognition in patients with parkinsonian and dementing conditions K.L. Leenders University Medical Center Groningen (UMCG)
|
|
- Verity Bell
- 8 years ago
- Views:
Transcription
1 Metabolic brain pattern recognition in patients with parkinsonian and dementing conditions K.L. Leenders University Medical Center Groningen (UMCG) TARGET conference Groningen, 5 april 2013
2 Content lecture Introduction Glucose consumption of the brain Image analysis Principal Component analysis Selected cases GLIMPS-project Conclusion
3 Introduction Differential diagnosis neurodegenerative brain diseases difficult in early phases overlapping clinical signs and symptoms Early diagnosis important Prognosis and management differ Auxiliary imaging investigations F-DOPA-PET/FP-CIT SPECT scan MRI [18F]-fluoro deoxy glucose (FDG) PET
4 Introduction [18F]-fluoro deoxy glucose (FDG) PET Glucose-analog Regions with high FDG-uptake (red/yellow) associated with brain activity Various brain diseases: different altered glucose utilisation patterns
5 Image-analysis Visual assessment Simple measures. Z-values. SPM comparisons with healthy control subjects Co-variance methods SSM-PCA: per group and per individual subject. (Scaled Subprofile Model Principal Component Analysis) Available: profiles of IPD, MSA, PSP en AD Individual subject score Future: improved techniques? Machine learning, supervised and unsupervised
6 Visual assessment individual FDG-PET scan PD MSA High FDG uptake PSP CBD Low FDG uptake DLB
7 Co-variance methods (SSM-PCA ) Voxel wise Scaled subprofile modeling (SSM) Principal component analysis (PCA) PCA identifies relations between brain regions which can not be seen readily by ordinary visual inspection Determines the chance that different voxels with increased or decreased activity are related to each other Pattern: contribution of each individual through his subject score to the disease specific profile Moeller et al. 1987, 1999; Eidelberg et al. 1994, 2009; Spetsieris et al. 2007, 2009, 2010
8 PDRP and PDCP expression (SSM) in 15 early PD patiënts Huang e.a (BRAIN)
9 Specificity and sensitivity between groups of patients by SSM-PCA
10 Selected cases
11 Z score Case (1) mr T, 62 yr Since 1 yr mask face, problems walking, balance problems and increased slowness Rigidity and bradykinesia left > right. UPDRS (III) 24 Suspicion M Parkinson Levodopa 3x 125 mg After some time concentration problems, depression, more balance disturbances, moderate response to levodopa D/ suspicion m. Parkinson, dd PSP controls PD Advice: FDG-PET scan
12 GLIMPS Case (1) mr T, 62 yr Subjectscore of 1 patient (mct scan) compared with the PD, AD, PSP and MSA covariance pattern PD14 pt op PDRP pt op ADRP pt op PSPRP pt op MSARP PD14 controls PD
13 Case (2) mv S, 42 yr Second opinion suspicion m. Parkinson Since 2 yr fatigue, slowness, stiffness left > right UPDRS (III) 45 Suspicion PD Management: increasing levodopa After 4 yrs moderate effect of levodopa and apomorfine, accelerated progression, swallowing difficult, incontinence for urine, wheel chair Suspicion MSA Advice FDG-PET
14 Case (2) mv S, 42 yr MSA17 Subjectscore of 1 patient (HR+ scan) compared with the MSA, PSP, PD and AD covariance pattern pt op MSARP pt op PSPRP pt op PDRP pt op ADRP MSA17-3
15 GLIMPS Identification metabolic covariance pattern AD via SSM/PCA analysis (cohort 1) * * z-score = 0,65 Sensitivity = 93,3% Specificity = 94,4% PPV = 93,3% NPV = 94,4% -1-2 leave-one-out z-scores healthy controls leave-one-out z-scores Alzheimer's Disease patients Submitted L.K. Teune, F. Strijkert, R.J. Renken, G.J. Izaks, J.J. de Vries, M. Segbers, J.B.T.M. Roerdink, R.A.J.O. Dierckx, K.L. Leenders.
16 GLIMPS Prospective individual patients tested on the AD pattern patients with memory complaints (cohort 2) individual patients probable AD individual patients non probable AD Submitted L.K. Teune, F. Strijkert, R.J. Renken, G.J. Izaks, J.J. de Vries, M. Segbers, J.B.T.M. Roerdink, R.A.J.O. Dierckx, K.L. Leenders.
17 Case (4) mr K, 59 yr Since 4 yr calculation problems at work. Since 2 yr word finding and orientation problems. In unfamiliar environments loses his way Apraxia, disturbed orientation and fronto-executive dysfunction. No clear memory disturbances MMSE 28/29 FAB 12/18 DD/ AD, FTD, CBD Advice MRI, FDG-PET
18 Case (4) mr K, 59 yr Subjectscore of 1 patient (HR+ scan) comapred with the AD, PD, PSP en MSA covariance pattern rswad07b.img pt op ADRP pt op PDRP pt op PSPRP pt op MSARP rswad07b.img -1
19 GLIMPS Improved classification using decision tree method Individual subject scores per component Classification 76 subjects at the same time Four groups Only 3 of 76 subjects wrongly classified In progress Johann Bernoulli Institute for Mathematics and Computer Science, RUG D. Mudali, L.K. Teune, R.J. Renken, K.L. Leenders, J.B.T.M. Roerdink
20 GLIMPS Glucose IMaging in Parkinsonian Syndromes National FDG-PET database project Website data entry Improved differential diagnosis for neurodegenerative brain diseases > 10 Dutch centers participate Start spring 2012
21 GLIMPS: clinical benefit and research Improved diagnosis in parkinsonian conditions Every patient who according to the practicing clinician might benefit from a FDG-PET scan. At short notice direct visual scan assessment Testing typical profiles Development of pattern recognition methods Supervised Unsupervised
22 GLIMPS Database
23 GLIMPS Feedback z-scores, patiënt Leeuwarden Klinische gegevens: Vrouw 53 jaar, bekend met M Parkinson sinds 4 jaar. Klachten: slikken verminderd, vallen, oogbewegingen niet afwijkend. Geen reactie op Levodopa. Vraagstelling: aanwijzingen voor PSP? FDG-PET visueel beeld:
24 GLIMPS Feedback z-scores, patiënt Leeuwarden Z-scores voor deze patiënt Conclusie: PSP patroon geëxprimeerd, overeenkomstig klinische verdenking. 0-1 pt op PDRP pt op MSARP pt op PSPRP pt op ADRP -2-3
25 GLIMPS Feedback z-scores, patiënt Roermond Klinische gegevens: Man, 70 jaar, bekend met parkinsonisme. Vraagstelling: MSA, IPD? Visuele beoordeling FDG-PET scan door nucleair geneeskundige Roermond: Verminderde FDG-stapeling pariëto occipitaal rechts tov links. Verminderde uptake in nucleus caudatus bdz (re>li) en thalamus rechts. Conclusie: geen specifiek patroon. FDG-PET visueel beeld:
26 GLIMPS Feedback z-scores, patiënt Roermond Z-scores voor deze patiënt 3 09_002 Conclusie: IPD patroon meest geëxprimeerd _002 0 pt op PDRP pt op MSARP pt op PSPRP pt op ADRP -1
27 Conclusions Network abnormalities in brain metabolism in neurodegenerative brain diseases proven Ready for practical application Better subgroups necessary to determine more profiles Elaboration into a system of functional and pathophysiological patterns instead of diseases?
28 Thank you
29
Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment
Primary Care Update January 28 & 29, 2016 Alzheimer s Disease and Mild Cognitive Impairment Kinga Szigeti, MD Associate Professor UBMD Neurology UB Department of Neurology Questions How do we differentiate
More informationSinemet (Parkinson's Disease) - Forecast and Market Analysis to 2022
Brochure More information from http://www.researchandmarkets.com/reports/2834728/ Sinemet (Parkinson's Disease) - Forecast and Market Analysis to 2022 Description: Sinemet (Parkinson s Disease) - Forecast
More informationWhat is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician
What is PD? Dr Catherine Dotchin MD MRCP Consultant Geriatrician Overview of presentation Case history Video example pre and post treatment Historical review PD in the UK Epidemiology and aetiology Making
More informationHow to test ocular movements in PSP Jan Kassubek
How to test ocular movements in PSP Jan Kassubek Universitätsklinik für Neurologie, Ulm Bedside Screening: PSP initially slowing of vertical saccades slowing of downward saccades is considered the hallmark
More informationNEUROIMAGING in Parkinsonian Syndromes
NEUROIMAGING in Parkinsonian Syndromes (Focus on Structural Techniques: CT and MRI) Dr. Roberto Cilia Parkinson Institute, ICP, Milan, Italy OUTLINE Primary Parkinsonism Idiopathic Parkinson s Disease
More informationPARKINSON S DISEASE AND PARKINSONISM. Dr Phil Wood Geriatrician, Waitemata DHB Clinical Unit Leader, Waikato DHB
PARKINSON S DISEASE AND PARKINSONISM Dr Phil Wood Geriatrician, Waitemata DHB Clinical Unit Leader, Waikato DHB OUTLINE Covering:- Why this is an important area of Medical and Psychiatric care The variety
More informationCRITERIA FOR AD DEMENTIA June 11, 2010
CRITERIA F AD DEMENTIA June 11, 2010 Alzheimer s Disease Dementia Workgroup Guy McKhann, Johns Hopkins University (Chair) Bradley Hyman, Massachusetts General Hospital Clifford Jack, Mayo Clinic Rochester
More informationCurrent evidence suggests that Parkinson s tends to develop
About Parkinson's Diagnosing Parkinson s Current evidence suggests that Parkinson s tends to develop gradually and it may be many months, even years, before the symptoms become obvious enough for you to
More information2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease
2012 Medical School for Actuaries Nov. 6-7, 2012 Session #1: Alzheimer s Disease Dylan Wint, M.D. ALZHEIMER DISEASE Dylan Wint, M.D. Lou Ruvo Center for Brain Health DEFINITIONS Cognitive related to thinking,
More informationMontreal Cognitive Assessment (MoCA) Debbie Froese, B.M.R.-O.T., B.A. Christine Knight, Ph.D.,R.Psych.
Montreal Cognitive Assessment (MoCA) Debbie Froese, B.M.R.-O.T., B.A. Christine Knight, Ph.D.,R.Psych. Community Geriatric Mental Health Model of Continuum of Cognition with Aging Normal Mild cognitive
More information2016 Programs & Information
Mayo Alzheimer s Disease Research Clinic Education Center 2016 Programs & Information BROCHURE TITLE FLUSH RIGHT for Persons & Families impacted by Mild Cognitive Impairment Alzheimer s Disease Dementia
More informationWhat is epilepsy? English
What is epilepsy? English WHAT IS EPILEPSY? An epileptic seizure is the term used for a temporary brain dysfunction due to a sudden and uncontrolled disturbance of the brain s electrical activity. Epilepsy
More informationLewy body dementia Referral for a Diagnosis
THE Lewy Body society The more people who know, the fewer people who suffer Lewy body dementia Referral for a Diagnosis Lewy Body Dementias REFERRAL FOR A DIAGNOSIS In the UK people with all forms of dementia
More informationMr James Garrard University of Leicester May 2014
Parkinson s disease exemplifies the art and science of geriatric medicine. Introduction First described by Dr. James Parkinson in the classic essay The Shaking Palsy in 1817 (1), Parkinson s disease is
More informationCase Studies, MCI, Clinical Trials and Care Management Support
Case Studies, MCI, Clinical Trials and Care Management Support These slides form part of a Clinical Education programme. To benefit fully and earn CME credits, please contact clinician@re-cognitionhealth.com
More informationMeeting the Needs of Aging Persons. Aging in Individuals with a
Meeting the Needs of Aging Persons with Developmental Disabilities Cross Network Collaboration for Florida Aging in Individuals with a Developmental Disability Module 3 Based on ADRC training developed
More informationBedside cognitive examination beyond the MMSE. Dr Richard Perry Dept of Neurosciences Imperial College
Bedside cognitive examination beyond the MMSE Dr Richard Perry Dept of Neurosciences Imperial College Overview Initial observations Cognitive rating scales Assessing cognitive domains Memory Language Visuospatial
More informationRörelserubbningar och Parkinson, hur svårt kan det vara. En översikt och problematisering av en folksjukdom Örjan Skogar, MD,PhD
Rörelserubbningar och Parkinson, hur svårt kan det vara En översikt och problematisering av en folksjukdom Örjan Skogar, MD,PhD Man räknar med att 11-19 personer /100 000 invånare insjuknar i Parkinson
More informationAlzheimer's: The Latest Assessment and Treatment Strategies
Questions from chapter 1 Alzheimer's: The Latest Assessment and Treatment Strategies 1) What is a loss of cognitive and intellectual powers without changes in consciousness. a) dementia b) delusions c)
More informationWelcome to the Medical Risk Webinar: a taster of Assessing and Managing Medical Risk for Insurers courses. 26 April 2013
Welcome to the Medical Risk Webinar: a taster of Assessing and Managing Medical Risk for Insurers courses 26 April 2013 1 Parkinson s Disease & Multiple Sclerosis Dr Nick Niven Jenkins 2 Movement Human
More informationBenefit of exercise for Parkinson s disease. Dr Florence Chang Movement disorder fellow
Benefit of exercise for Parkinson s disease Dr Florence Chang Movement disorder fellow Objectives Review evidence of exercise in animal models of PD Review evidence of exercise benefitting patients with
More informationSLEEP AND PARKINSON S DISEASE
A Practical Guide on SLEEP AND PARKINSON S DISEASE MICHAELJFOX.ORG Introduction Many people with Parkinson s disease (PD) have trouble falling asleep or staying asleep at night. Some sleep problems are
More informationMultiple System Atrophy
Multiple System Atrophy U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health Multiple System Atrophy What is multiple system atrophy? Multiple system atrophy
More informationSummary chapter 2 chapter 2
Summary Multiple Sclerosis (MS) is a chronic disease of the brain and the spinal cord. The cause of MS is unknown. MS usually starts in young adulthood. In the course of the disease progression of neurological
More informationParkinson disease and parkinsonism: Clinical Questions
Parkinson disease and parkinsonism: Clinical Questions Nicolaas I. Bohnen, MD, PhD University of Michigan & Ann Arbor VAMC From the An Essay of Shaking Palsy James Parkinson (Sherwood, Neely, and Jones,
More informationNursing Care of Patients with Movement Disorders. Catholic Health 2 nd Annual Neurorehab Symposium November 1, 2014
Nursing Care of Patients with Movement Disorders Catholic Health 2 nd Annual Neurorehab Symposium November 1, 2014 Types of Movement Disorders Parkinson s disease Huntington s disease Dystonia Tremors
More informationCommunity Network for Dementia and Critical Path in Japan
Research and Reviews Community Network for Dementia and Critical Path in Japan JMAJ 54(5): 305 309, 2011 Satoshi ORIMO* 1 Abstract In Setagaya City of Tokyo, regional hospitals and medical associations
More informationParkinson s Disease: Deep Brain Stimulation and FDOPA-PET
Parkinson s Disease: Deep Brain Stimulation and FDOPA-PET The work described in this thesis was performed at the Department of Neurology, University Medical Center, Groningen (the Netherlands). A.T. Portman
More informationParkinsonism is an umbrella term used to cover a range of conditions.
Symptoms and lifestyle Parkinsonism Parkinsonism is an umbrella term used to cover a range of conditions. These conditions share the symptom of slow movement, sometimes with tremor, rigidity and problems
More informationDementia Causes and Neuropsychological Evaluation of the Older Adult
Dementia Causes and Neuropsychological Evaluation of the Older Adult Laurie N. Culp, Ph.D. Pate and Culp Psychological Assoc. 2440 Lawrenceville Highway Suite 200 Decatur, GA 30033 678-595-0062 lculp@emory.edu
More informationSubstance Abuse in the Elderly
Substance Abuse in the Elderly Roseann Mulligan DDS, MS Definitions: Abuse: to use wrongly, badly, excessively; to misuse Misuse: to use incorrectly or improperly; to abuse Types of Substances Implicated
More informationIII./3.1.2. Parkinsonian syndrome (parkinsonism, atypical parkinsonian disorders) in neurodegenerative diseases
III./3.1.2. Parkinsonian syndrome (parkinsonism, atypical parkinsonian disorders) in neurodegenerative diseases III./3.1.2.1. Multiple System Atrophy (MSA) MSA is a sporadic, adult onset degenerative neurological
More informationObjectives. Evaluation of Memory Loss. Cognitive Impairment. Clinical Questions. Medicare Wellness Visit
Evaluation of Memory Loss and Mild Cognitive Impairment Skotti Church, MD Geriatrics Grand Rounds 4/3/2014 Objectives 1. Describe recommendations and tools for evaluation of cognitive impairment 2. Define
More informationCopywrite - Eric Freitag, Psy.D., 2012
Diagnosis, Intervention and Care for Patients With Cognitive Impairment Eric J. Freitag, Psy.D, FACPN Diplomate, American College of Professional Neuropsychology Mt. Diablo Memory Center Founder/Executive
More informationManagement of Parkinson s Disease in Primary Care
Management of Parkinson s Disease in Primary Care Dr June Tan National University Hospital System (NUHS) Division of Neurology Senior Consultant Topics: Diagnosing PD Choice of medication in the de novo
More informationPARKINSON S DISEASE INTRODUCTION. Parkinson s disease is defined as a disease of the nervous system that affects voluntary movement.
PARKINSON S DISEASE INTRODUCTION Parkinson s disease is a disorder of the brain and the nervous system. It is one of the more common neurological diseases in people over the age of 60, and it is more common
More informationSOCIAL SECURITY ADMINISTRATION Office of Disability Adjudication and Review DECISION JURISDICTION AND PROCEDURAL HISTORY
P-6 SOCIAL SECURITY ADMINISTRATION Office of Disability Adjudication and Review DECISION IN THE CASE OP Kristina Marie Townsend (Claimant) (Wage Earner) CLAIM FOR Period of Disability and Disability Insurance
More informationNormal and Abnormal Aging and the Brain. Joel Kramer, PsyD Saul Villeda, PhD Kristine Yaffe, MD
Normal and Abnormal Aging and the Brain Joel Kramer, PsyD Saul Villeda, PhD Kristine Yaffe, MD The myth of cognitive decline The myth of cognitive decline Individual change varies Individual change varies
More informationPARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS
PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS De Anna Looper, RN CHPN Corporate Clinical Consultant / Legal Nurse Consultant Carrefour Associates L.L.C. PARKINSON S DISEASE IN LONG-TERM-CARE SETTINGS
More informationSIGN. Diagnosis and pharmacological management of Parkinson s disease. January 2010. A national clinical guideline
SIGN Scottish Intercollegiate Guidelines Network Part of NHS Quality Improvement Scotland Help us to improve SIGN guidelines - click here to complete our survey 113 Diagnosis and pharmacological management
More informationImaging Markers of Brain Network Dysfunction in Multiple Sclerosis
Faculty of Medicine & Health Sciences School of Medicine Radiological Sciences Research Group The University of Nottinham University Park Nottingham NG7 2RD t: +44 (0)115 823 0018 f: +44 (0)115 823 0004
More informationWhy study clinical neuropsychology?
University Leiden, The Netherlands Master (MSc) in Clinical Neuropsychology H.A.M.Middelkoop@lumc.nl www.neuropsychologie.leidenuniv.nl Why study clinical neuropsychology? You are interested in: brain/behavior
More informationStephen L. Benson, Psy.D. November 17, 2015
Stephen L. Benson, Psy.D. November 17, 2015 Biomedical view of dementia Lyman (1989) suggested that the biomedical view of dementia includes three features: First, dementia is pathological and individual,
More informationThe Role of Neuropsychological Testing in Guiding Decision- Making Related to Dementia
The Role of Neuropsychological Testing in Guiding Decision- Making Related to Dementia By Scott Knight, Director, SLR Diagnostics & Assessments, a division of Sibley & Associates Inc., and Konstantine
More informationAlzheimer s disease. What is Alzheimer s disease?
Alzheimer s disease What is Alzheimer s disease? What we know about dementia and Alzheimer s disease Alzheimer s disease is the most common of a large group of disorders known as dementias. It is an irreversible
More informationPrediction of the MoCA and the MMSE in Out-patients with the risks of cognitive impairment
Prediction of the MoCA and the MMSE in Out-patients with the risks of cognitive impairment Teresa Leung Therapist Prince of Wales Hospital 7 th May, 2012 Outline of Presentation Introduction Study Objectives,
More informationABI Statement of Best Practice for Critical Illness Cover. A Consultation Paper
ABI Statement of Best Practice for Critical Illness Cover A Consultation Paper June 2010 1. Background and Purpose of this Paper 1.1 The Statement of Best Practice for Critical Illness Cover (the Statement
More informationHoehn and Yahr Staging of Parkinson's Disease
Hoehn and Yahr Staging of Parkinson's Disease, Unified Parkinson Disease Rating Scale (UPDRS), and Schwab and England Activities of Daily Living Disclaimer: The information and reference materials contained
More informationHow To Find Out If The Gulf War And Health Effects Of Serving In The Gulf Wars Are Linked To Health Outcomes
Gulf War and Health: Update of Health Effects of Serving in the Gulf War Statement of Stephen L. Hauser, M.D. Professor and Chair of Neurology University of California, San Francisco, School of Medicine
More informationSteps to getting a diagnosis: Finding out if it s Alzheimer s Disease.
Steps to getting a diagnosis: Finding out if it s Alzheimer s Disease. Memory loss and changes in mood and behavior are some signs that you or a family member may have Alzheimer s disease. If you have
More informationFollow-up Form B3: Evaluation Form Unified Parkinson s Disease Rating Scale (UPDRS 1 ) Motor Exam
phone: (206) 543-8637; fax: (206) 616-5927 e-mail: naccmail@u.washington.edu website: www.alz.washington.edu NACC Uniform Data Set (UDS) Follow-up Form B3: Evaluation Form Unified Parkinson s Disease Rating
More informationParkinson s Disease - A Junior Doctor s Survival Guide
Parkinson s Disease - A Junior Doctor s Survival Guide Professor Richard Walker Consultant Geriatrician Hon. Professor of Ageing & Interna
More informationSocial Security Disability Insurance and young onset dementia: A guide for employers and employees
Social Security Disability Insurance and young onset dementia: A guide for employers and employees What is Social Security Disability Insurance? Social Security Disability Insurance (SSDI) is a payroll
More informationIntellectual Symptoms Amnesia: Loss of memory function
Definition of Dementia (de mens) Latin for out of mind Permanent loss of multiple intellectual functions Alois Alzheimer first described this disease in 1906 in a brain specimen from an autopsy. Alzheimer
More informationhttp://images.tutorvista.com/content/control5coordination/human5brain.jpeg!! 387
http://images.tutorvista.com/content/control5coordination/human5brain.jpeg!! 387! 388! http://my.fresnounified.org/personal/lygonza/gonzalez/neuron/neuron5synapse%20communication.png!! http://www.urbanchildinstitute.org/sites/all/files/databooks/2011/ch15fg25communication5between5neurons.jpg!!
More informationMorphological analysis on structural MRI for the early diagnosis of neurodegenerative diseases. Marco Aiello On behalf of MAGIC-5 collaboration
Morphological analysis on structural MRI for the early diagnosis of neurodegenerative diseases Marco Aiello On behalf of MAGIC-5 collaboration Index Motivations of morphological analysis Segmentation of
More informationUnderstanding FTD Clinical Trials Continuing Education Training FTD Support Group Facilitators May 13, 2013
Understanding FTD Clinical Trials Continuing Education Training FTD Support Group Facilitators May 13, 2013 Our Shared Vision We envision a world where frontotemporal degeneration is understood, effectively
More informationSummary of the risk management plan (RMP) for Rasagiline ratiopharm (rasagiline)
EMA/744222/2014 Summary of the risk management plan (RMP) for Rasagiline ratiopharm (rasagiline) This is a summary of the risk management plan (RMP) for Rasagiline ratiopharm, which details the measures
More informationA Proposed Data Mining Model for the Associated Factors of Alzheimer s Disease
A Proposed Data Mining Model for the Associated Factors of Alzheimer s Disease Dr. Nevine Makram Labib and Mohamed Sayed Badawy Department of Computer and Information Systems Faculty of Management Sciences,
More informationAn Introduction to Lewy Body Dementia
An Introduction to Lewy Body Dementia A special publication for people newly diagnosed with Lewy body dementia and those still seeking answers. You don t have to face LBD alone. Increasing Knowledge Sharing
More informationDonepezil hydrochloride (Aricept) Drug treatment for Alzheimer s disease
IS 11 October 2011 Information sheet Donepezil hydrochloride (Aricept) Drug treatment for Alzheimer s disease Introduction... 1 How does Aricept work?... 1 Who might benefit from Aricept?... 2 What effect
More informationDiabetes, hypertension and a lot more `in the elderly` JORIS SCHAKEL INTERNIST- CLINICAL GERIATRICIAN JGSCHAKEL@SEHOS.CW
Diabetes, hypertension and a lot more `in the elderly` JORIS SCHAKEL INTERNIST- CLINICAL GERIATRICIAN JGSCHAKEL@SEHOS.CW IT`S HARD TO GIVE GENERAL ADVICE! ``The Elderly`` Heterogeneous group ;widely varying
More informationCREATIVE DEMONSTRATIVE EVIDENCE: ADDING THE MIDAS TOUCH. We all know that the use of demonstrative evidence can be crucial to the jury s ability to
CREATIVE DEMONSTRATIVE EVIDENCE: ADDING THE MIDAS TOUCH A. Introduction We all know that the use of demonstrative evidence can be crucial to the jury s ability to understand complex issues at trial. There
More informationKnowledge-based systems and the need for learning
Knowledge-based systems and the need for learning The implementation of a knowledge-based system can be quite difficult. Furthermore, the process of reasoning with that knowledge can be quite slow. This
More informationGYMR A4 Study Long Form Film
VIDEO INTRO GRAPHICS GRAPHIC DR. SPERLING AUDIO 0:00 [Music & Graphics Only] 0:05 The A4 Study is a landmark clinical trial to prevent the memory loss associated with Alzheimer s disease. 0:10 Thank you
More informationConcepts of Normality and Abnormality
Normal and Abnormal Behavior Concepts of Normality and Abnormality Psychology 311 Abnormal Psychology Listen to the audio lecture while viewing these slides 1 2 What is Normal Behavior? What is Abnormal
More informationClinical Research in Parkinson s Disease: The Advances, Challenges, and Importance of Rater Training
Clinical Research in Parkinson s Disease: The Advances, Challenges, and Importance of Rater Training Marian A. Ormont, MD epharmasolutions, A WIRB-Copernicus Group Company April is Parkinson s disease
More informationEmergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
More informationSLEEP DIFFICULTIES AND PARKINSON S DISEASE Julie H. Carter, R.N., M.S., A.N.P.
SLEEP DIFFICULTIES AND PARKINSON S DISEASE Julie H. Carter, R.N., M.S., A.N.P. Problems with sleep are common in Parkinson s disease. They can sometimes interfere with quality of life. It is helpful to
More informationDementia with Lewy bodies
IS 18 April 2011 Information sheet Dementia with Lewy bodies Introduction... 1 Key points... 1 What is dementia with Lewy bodies?... 1 How many people are affected by DLB?.. 2 What is the cause?... 2 Symptoms...
More informationGOING BEYOND RISK REDUCTION: PHYSICAL EXERCISE MAY BE AN EFFECTIVE TREATMENT FOR ALZHEIMER S DISEASE AND VASCULAR DEMENTIA
CONTACT: Alzheimer s Association AAIC newsroom, 202-249-4002, media@alz.org Niles Frantz, Alzheimer s Association, 312-335-5777, niles.frantz@alz.org GOING BEYOND RISK REDUCTION: PHYSICAL EXERCISE MAY
More informationName of Policy: Dopamine Transporter Imaging with Single Photon Emission Computed Tomography (DAT-SPECT)
Name of Policy: Dopamine Transporter Imaging with Single Photon Emission Computed Tomography (DAT-SPECT) Policy #: 504 Latest Review Date: July 2014 Category: Radiology Policy Grade: B Background/Definitions:
More informationABC s of Parkinson s Disease 4/29/15 Karen Parenti, MS, PsyD
ABC s of Parkinson s Disease 4/29/15 Karen Parenti, MS, PsyD What is Parkinson s Disease? Parkinson's disease is a progressive disorder of the nervous system that affects movement. It develops gradually,
More informationCircadian rhythms and functioning in neurodegenerative disease
Circadian rhythms and functioning in neurodegenerative disease Eus Van Someren Netherlands Institute for Neuroscience & Leiden University Medical Center Amsterdam, The Netherlands Acknowledgement S&C team
More informationAge Associated Cognitive Decline and Mild Cognitive Impairment (MCI)
Age Associated Cognitive Decline and Mild Cognitive Impairment (MCI) Mike R. Schoenberg, PhD, ABPP-CN Diplomate, American Board of Clinical Neuropsychology Licensed Psychologist Departments of Psychiatry
More informationPersonal Health Record
Personal Health Record Contents Section 1: Personal details (pages 4 6) Within this section you can note all information about you, next of kin, important health information and general medical history.
More informationStaging and Treatment of Dementia
Staging and Treatment of Dementia Ami Hall DO 10/25/14 1 Objectives What are the two most common types of dementias seen in a primary care office How are they staged What treatments are available Definition
More informationMultiple Sclerosis (MS)
Multiple Sclerosis (MS) Purpose/Goal: Care partners will have an understanding of Multiple Sclerosis and will demonstrate safety and promote independence while providing care to the client with MS. Introduction
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationJohns Hopkins Memory & Alzheimer s Treatment Center
Memory is The Memory Center has not only provided great care to my husband, but also has helped me learn to care for myself while caring for him. - Sylvia Mackey Have you forgotten someone s name you should
More informationPrimary Endpoints in Alzheimer s Dementia
Primary Endpoints in Alzheimer s Dementia Dr. Karl Broich Federal Institute for Drugs and Medical Devices (BfArM) Kurt-Georg-Kiesinger-Allee 38, D-53175 Bonn Germany Critique on Regulatory Decisions in
More informationHeadache: Differential diagnosis and Evaluation. Raymond Rios PGY-1 Pediatrics
Headache: Differential diagnosis and Evaluation Raymond Rios PGY-1 Pediatrics You are evaluating a 9 year old male patient at the ED brought by his mother, who says that her son has had a fever, cough,
More informationParkinson s Disease and Dementia. Dr N Samaniego Consultant Physician and Geriatrician
Parkinson s Disease and Dementia Dr N Samaniego Consultant Physician and Geriatrician Case 68 year old female. Off legs for a few months, O/E no neurological deficit. -Slowing down -Needs help with dressing,
More informationDementia One Day Essentials 2015
Dementia One Day Essentials 2015 1 Dementia One Day Essentials 2015 2 At Risk of Dementia: Mild Cognitive Impairment and Other Non-Dementia Diagnoses Dr Jill Rasmussen Declaration of Interests NHS: GP
More informationPARTNERING WITH YOUR DOCTOR:
PARTNERING WITH YOUR DOCTOR: A Guide for Persons with Memory Problems and Their Care Partners Alzheimer s Association Table of Contents PARTNERING WITH YOUR DOCTOR: When is Memory Loss a Problem? 2 What
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 7/30/2013 Most Recent Review Date (Revised): 6/2/2015 Effective Date: 8/1/2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER
More informationParkinson s Disease: General Information
Parkinson s Disease: General Information Does PD come in stages? If so, how many stages? Hubert Fernandez, MD: Staging provides an artificial classification of a patient's illness severity but, in reality,
More informationGraphical tasks to aid in diagnosing and monitoring Parkinson s disease
Graphical tasks to aid in diagnosing and monitoring Parkinson s disease Esther J. Smits The studies described in this thesis were part of the DiPAR project for which funding was received from the EC in
More informationJournal Club. Parkinsonismo iatrogeno
PROGETTO UNIVA 2013 Journal Club Parkinsonismo iatrogeno Pietro Gareri, MD, PhD Geriatra ASP Catanzaro Lamezia Terme 3 Luglio 2013 Drug-induced parkinsonism (DIP) was recognized in the early 1950s as a
More information1 st December 2009. Cardiff Crown Court. Dear. Claimant: Maurice Kirk Date of Birth: 12 th March 1945
Ref: PMK/MT 1 st December 2009 Cardiff Crown Court Dear Claimant: Maurice Kirk Date of Birth: 12 th March 1945 I have been instructed by Yorkshire Law Solicitors to comment on the SPECT scan images undertaken
More informationBig Data: Rethinking Text Visualization
Big Data: Rethinking Text Visualization Dr. Anton Heijs anton.heijs@treparel.com Treparel April 8, 2013 Abstract In this white paper we discuss text visualization approaches and how these are important
More informationExercise Prescription Case Studies
14 Exercise Prescription Case Studies 14 14 Exercise Prescription Case Studies Case 1 Risk Stratification CY CHAN is a 43-year-old man with known history of hypertension on medication under good control.
More informationDrugs and Treatments for Ataxia. Christopher M. Gomez The University of Chicago
Drugs and Treatments for Ataxia Christopher M. Gomez The University of Chicago Two types of treatments Disease- modifying (neuroprotecave) SymptomaAc Disease- modifying Very few opaons right now. Most
More information1: Motor neurone disease (MND)
1: Motor neurone disease (MND) This section provides basic facts about motor neurone disease (MND) and its diagnosis. The following information is an extracted section from our full guide Living with motor
More informationMontreal Cognitive Assessment (MoCA) as Screening tool for cognitive impairment in mtbi.
Montreal Cognitive Assessment (MoCA) as Screening tool for cognitive impairment in mtbi. Suresh Kumar, M.D. AUTHOR Director of: Neurology & Headaches Center Inc. Neurocognitve &TBI Rehabilitation Center
More informationConcussion Management Return to Play Protocol
Concussion Management Return to Play Protocol Returning to play following a concussion involves a stepwise progression once the individual is symptom free. There are many risks to premature return to play
More informationNURSING B29 Gerontology Community Nursing. UNIT 2 Care of the Cognitively Impaired Elder in the Community
NURSING B29 Gerontology Community Nursing UNIT 2 Care of the Cognitively Impaired Elder in the Community INTRODUCTION The goal of this unit is for the learner to be able to differentiate between delirium,
More informationCholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW
Cholinesterase inhibitors and memantine use for Alzheimer s disease TOPIC REVIEW Diagnosis of Dementia : DSM-IV criteria Loss of memory and one or more other cognitive abilities Aphasia Apraxia Agnosia
More informationMalignant Pleural Diseases Advances Clinicians Should Know F Gleeson
Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson The following relevant disclosures, conflicts of interest and/ or financial relationships exist related to this presentation: Consultant
More informationAttention & Memory Deficits in TBI Patients. An Overview
Attention & Memory Deficits in TBI Patients An Overview References Chan, R., et.al.. (2003). Are there sub-types of attentional deficits in patients with persisting post- concussive symptoms? A cluster
More information